Back

AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting

30 June 2021 (16:11 - 16:28)
Organised by:
Congress Presentation Part of: Late-Breaking Trials 2 Pharmacotherapy HFA Premium Access Heart Failure 2021

About the speaker

Photo
Professor Phil Mc Ewan

Health Economics and Outcomes Research Ltd, Cardiff (United Kingdom of Great Britain & Northern Ireland)

2 More presentations in this session

Presentation thumbnail
Improving cognitive function in patients with heart failure - The Cognitive Training in Heart Failure Study (CogTrain-HF)
Miss S. Wedegaertner (Homburg, DE)
Slides Video
Presentation thumbnail
Vericiguat in patients with atrial fibrilation and heart failure with reduced ejection fraction: insights from the VICTORIA (VerICiguaT global study in subjects with HFrEF)
Professor P. Ponikowski (Wroclaw, PL)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Trials 2
Video

The Event

Event poster

Heart Failure 2021

30 June 2021 16:11 CET
You may be interested in
thumbnail
Congress Session
Acute heart failure therapies: from clinical trials to clinical practice
thumbnail
Congress Session
Devices in acute heart failure
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources